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Introduction
With a rapid proliferation, resistance to apoptosis and highly invasive and metastatic properties, anaplastic thyroid carcinoma (ATC) is one of the most aggressive types of human cancer (1) . ATC cells can arise either de novo or from a dedifferentiation of papillary (PTC) or follicular (FTC) thyroid carcinoma cells rendering them highly mitotic and metastatic. The 5-year survival rate of ATC is less than 7% and current therapies, comprising of radical thyroidectomy, radiosensitizing chemotherapy and external beam radiotherapy, are rarely curative (2) . Few efforts have been made at targeting thyroid cancer by immunotherapy. Dendritic cell (DC) vaccination trials against medullary thyroid cancer (MTC) have been performed using full-length calcitonin-primed DCs which have shown antitumor activity (3) . In contrast to PTC and FTC, where several tumor-associated antigens (TAAs) have been identified, there are no immunogenic proteins described for ATC (4) However, few clinical responses have been observed in patients with solid tumors (6) . In an ongoing clinical study we observed that 7 out of 14 patients with advanced solid tumors had stable disease after infusions with expanded NK cells. Two of the patients developed acute thyroiditis (7) . The activity of NK cells is regulated through a balance of activating and inhibitory signals emanating from a repertoire of receptors expressed on the cell surface. One of the most studied receptors is the naturalkiller group 2, member D (NKG2D) receptor, which is constitutively expressed on NK cells.
Expression of NKG2D is not necessary for NK cell development, but is critical for immunosurveillance of cancer (8) . Upon binding of the NKG2D-receptor with its ligands, major histocompatibility complex class I chain-related chain A/B (MICA/B) or the UL16 binding proteins previously been shown that tumors over expressing ULBP2 through activation of wild type p53 are more sensitive to lysis by NK cells (10) .
Intratumoral infiltration of NK cells has been reported to correlate with good prognosis (11, 12) .
Tumor cells can be stimulated to secrete the chemokines CXCL9, CXCL10 and CXCL11, which attract NK cells expressing the chemokine receptor CXCR3 (13) . In mice, the expression of CXCR3 on NK cells is essential for homing towards CXCL10-producing solid tumors and in humans, CXCL10-secretion from tumors is found to be a strong prognostic marker for infiltration of cytotoxic T-cells which in turn correlates with a favorable prognosis (14, 15) . Although NK cells do infiltrate tumor cells, it is well known that tumor cells are immunosuppressive and limit the activity of NK cells. Among the more studied NK cell immunosuppressive factors are tumor growth factor-beta (TFGβ), arginase-1, indoleamine 2,3-dioxygenase (IDO), inducible nitric oxide (iNOS), and prostaglandin-E2 (PGE2) which have been shown to downregulate activating receptors, including NKG2D, as well as suppress NK cell cytotoxicity (16) . Thus, tumors that exert little immunosuppression, secrete high amounts of CXCL10 and express high levels of NKG2D-ligands are suitable for cell therapy using ex vivo expanded NK cells which we previously have described to be more cytotoxic than resting NK cells (17) . In the present study, we sought to investigate if ATC is a suitable target for NK cell therapy. We found that low-passage ATC cell lines express high levels of the NKG2D-ligands ULBP2/5/6 and produce high amounts of CXCL10 in response to low-dose IFNγ.
As a consequence, ATC cell lines were highly susceptible to NK cell lysis and effectively chemoattracted NK cells respectively. We further found that in ATC patients, intratumoral NK cells are positive for CXCR3, but display a suppressed phenotype compared to peripheral blood NK cells.
The direct suppressive effect of ATC cells was pronounced in cyclooxygenase-2 (COX-2) positive cell lines and blockade of PGE2 reduced the suppressive effect of ATC on NK cells. Based on our findings we propose that ATC represent a good candidate target for NK cell-based adoptive therapy.
Research. thyroid nodules were punctured using a 0.6 or 0.7 x 30 mm needle. Peripheral blood mononuclear cells (PBMC) were isolated from whole blood using density centrifugation. Cells (FNA and PBMC)
were stained with fluorescence-conjugated monoclonal antibodies against human CD3, CD56, NKG2D, CD69, CXCR3, CD11c, MICA/MICB, IgG1-PE, IgG1-APC, 7AAD (Biolegend), ULBP1, ULBP2/5/6, ULBP3 (R&D systems), and LIVE/DEAD marker (Invitrogen) and analyzed by flow cytometry. All flow cytometry data was acquired on an LSRII flow cytometer (BD Biosciences) and analyzed using the FlowJo software (Tree Star). Table 2 ). The U-Hth cell lines and C643 and SW1736 were kindly provided by Dr. Nils-Erik Heldin (Uppsala University, Sweden). The K562, MOLT-4 and EST112 cell lines were purchased from ATCC or ESTDAB (http://www.ebi.ac.uk/ipd/estdab/). The remaining cell lines were not verified within 6 months of manuscript submission. All cell lines were maintained in RPMI1640 medium supplemented with 10% FBS. Cell lines were stained with fluorescence-conjugated monoclonal antibodies against HLA-ABC, MICA/B (Biolegend), ULBP1, ULBP-2/5/6 and ULBP3 (R&D systems). Intracellular flow cytometry staining for COX-2 (Biolegend) was performed using a detergent-based permeabilization protocol (BD Biosciences). Tumor cells were seeded at 2 x 10 5 cells/well in a 24-well plate and incubated at 37°C over night. The following day, recombinant human IFN-γ (Peprotech) was added to the cells and incubated over night. Supernatants were collected and analyzed for CXCL10 by ELISA according to the manufacturer's instructions (R&D systems).
Research. Bethesda, MD, USA). Where indicated, human CXCL10 capture antibody (840420, R&D systems) was present in the lower wells during the migration assay.
Immunohistochemistry. Paraffin-embedded tissues were sectioned and stained with polyclonal goat anti-human ULBP2/5/6 (polyclonal goat IgG, AF1298, R&D systems) or polyclonal rabbit anti-human CXCL10, PAB19527, Abnova).Slides were deparaffinized, rehydrated and subsequently boiled in citrate buffer (pH 6). Slides were blocked with 0.5% hydrogen peroxide (30 min) followed by 5% horse serum (30 min). Primary antibodies diluted in 1% BSA were added and incubated over night at 4°C. Horse anti-goat secondary antibody diluted in 1% BSA was added to the slides and incubated at room temperature (RT) for 30 min. ABC peroxidase solution (Vector laboratories) was added to the slides and incubated for 30 min at RT followed by staining with DAB (3,3 diamino-benzidine, Vector laboratories) according to the manufacturer's instructions. Slides were stained with haematoxylin for 1 min and dehydrated using EtOH and Xylen and were subsequently mounted using permanent mounting media (Pertex, Histolab products AB).
Results

ATC cell lines are sensitive to lysis by expanded NK cells
In vitro, the majority of ATC cell lines were sensitive to lysis by expanded NK cells and several of the cell lines were equally or more sensitive to NK cell lysis than the NK cell sensitive cell line K562. In contrast, the PTC cell lines were less sensitive to NK cell lysis than the ATC cell lines ( Figure 1A Figure 3D ). Furthermore, ATC cell lines silenced for ULBP2 was significantly less susceptible to NK cell-mediated lysis (data not shown).
Thus, the ULBP2 receptor may represent the major NKG2D-ligand responsible for the sensitivity of ATC cell lines. We were able to isolate and expand NK cells from one ATC patient from whose tumor we were also able to establish a cell line. In an autologous cytotoxicity assay against the LUTC-17 cell line, we found that the NK cells killed the LUTC-17 cell lines and upon receptor blockade with ULBP2/5/6-antibody, the lysis was reduced by 47.8% while blocking of NKG2D on NK cells resulted in 80.4% reduced lysis (Supplemental figure 1C) . Importantly, blockade of MHC class I on tumor cells did not increase the lysis significantly. The NK cell-mediated lysis of autologous ATC cells in absence or presence of MHC class I blocking antibody was 30.7% or 37.0% respectively (data not shown).
Research. Figure 5C ). Importantly, a reduced expression of NKG2D on NK cells was observed in FNA compared with PBMC in 5 out of 6 patients although the difference was not statistically significant. In one patient, the NKG2D expression was elevated on intratumoral NK cells (p = 0.35, Figure 5D ).
ATC cell lines expressing COX-2 suppress NK cells via PGE2
Given the suppressed phenotype of ATC-infiltrating NK cells, we sought to elucidate the mechanism 
after neutralization of PGE2 ( Figure 6C ). Of note, no difference in susceptibility to NK cell killing was observed between COX-2 positive and COX-2 negative ATC cell lines.
Research. (25, 26) and that ectopic expression of NKG2D-ligands in mice results in NK cells overcoming MHC class I-induced inhibition, thus promoting tumor rejection (27) . ULBP2 has characteristics that distinguish it from ULBP1 and ULBP3. The ULBP1-3 molecules are all anchored to the plasma membrane via a glycosylphophatidylinositol (GPI) domain. However, it has been shown that ULBP2, but not ULBP1 and -3 can relocate to the cell surface in the absence of a GPI moiety as a transmembrane protein which allows for more stable interaction with NKG2D-receptors on NK cells 
dim NK cells are preferentially eliminated either by susceptibility to apoptosis or to suppression by reactive oxygen species present in the tumor microenvironment (39, 40) . We observed that in PBMC from ATC patients, CXCR3 is predominantly expressed on CD56 bright NK cells Tumor cells were pretreated with ULBP2/5/6-specific blocking antibody (1 µg/ml) 30 minutes prior and during the cytotoxicity assay. Effector-to-target ratio was 3:1 except for LUTC-10 where it was 0.3:1. Paired two-tailed t-test was used to calculate statistical significance. 
